Comparing Pharming Group (NASDAQ:PHAR) & Dyadic International (NASDAQ:DYAI)

Dyadic International (NASDAQ:DYAI) and Pharming Group (NASDAQ:PHAR) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, dividends and analyst recommendations.

Analyst Recommendations

This is a summary of current recommendations for Dyadic International and Pharming Group, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyadic International	1	0	1	0	2.00
Pharming Group	2	0	3	0	2.20

Dyadic International presently has a consensus price target of $3.00, indicating a potential upside of 558.18%. Pharming Group has a consensus price target of $38.67, indicating a potential upside of 296.58%. Given Dyadic International’s higher possible upside, research analysts plainly believe Dyadic International is more favorable than Pharming Group.

Profitability

This table compares Dyadic International and Pharming Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Dyadic International	-201.43%	-2,920.31%	-84.77%
Pharming Group	2.51%	3.40%	1.90%

Volatility & Risk

Dyadic International has a beta of 0.96, indicating that its share price is 4% less volatile than the S&P 500. Comparatively, Pharming Group has a beta of -0.05, indicating that its share price is 105% less volatile than the S&P 500.

Earnings & Valuation

This table compares Dyadic International and Pharming Group”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyadic International	$1.33 million	13.70	-$7.36 million	($0.23)	-1.98
Pharming Group	$376.13 million	1.83	$2.85 million	$0.12	81.25

Pharming Group has higher revenue and earnings than Dyadic International. Dyadic International is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

28.0% of Dyadic International shares are owned by institutional investors. Comparatively, 0.0% of Pharming Group shares are owned by institutional investors. 20.9% of Dyadic International shares are owned by company insiders. Comparatively, 2.1% of Pharming Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Pharming Group beats Dyadic International on 9 of the 14 factors compared between the two stocks.

About Dyadic International

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.